| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd202a425419b9b183190425474b5bd9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5a362e09fab27aafc8bbaaada2440e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e31c9bf060030dd1d746db4b707245d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ee11b1ea0b6f21b358b1496a098501b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7331abc9f53062bfd774619b1cb53249 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-24 |
| filingDate |
2005-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a719e82e9d4d0ccd01d914cf3660bc4f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a78a029b984ea4c948f3ae39664fa8f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcddc624d4e5d0f3c0e5c939d9d4a583
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7155ddbee47adb422d75d3ae68781c12 |
| publicationDate |
2006-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006007509-A2 |
| titleOfInvention |
Epidermal growth factor receptor antagonists and methods of use |
| abstract |
The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of EGFR activity is indicated. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2044246-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009543071-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2044246-A2 |
| priorityDate |
2004-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |